Treatment options for early prostate cancer

Urology

Volumn 52, Issue 6, 1998, Pages 948-962

  Kirby, Roger ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ESTROGEN DERIVATIVE; GONADORELIN DERIVATIVE; STEROID;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; EARLY CANCER; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING;

CRYOTHERAPY; HUMANS; LASERS; MALE; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032402160     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00428-2     Document Type: Review

References (192)

1. Black R.J., Bray F., Ferlay J., et al. Cancer incidence and mortality in the European Union cancer registry data and estimates of national incidence for 1990 . Eur J Cancer. 33:1997;1075-1107.
2. Parker S.L., Tong T., Bolden S., et al. Cancer statistics 1997. CA Cancer J Clin. 47:1997;5-27.
3. Wingo P.A., Tong T., Bolden S. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin. 47:1997;239-242.
4. Alexander F.E., Boyle P. The rise in prostate cancer myth or reality? Garraway M.J. The Epidemiology of Prostate Disease. 1995;192-202 Springer, New York.
5. Boyle P., Maisonneuve P., Napalkov P. Incidence of prostate cancer mortality will double by the year 2030 the argument for . Eur Urol. 29:(suppl 2):1996;3-9.
6. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer. 55:1993;891-903.
7. Boyle P. Prostate cancer 2000 evolution of an epidemic of unknown origin . Denis L. Prostate Cancer 2000. 1994;5-11 Springer-Verlag, Heidelberg.
8. Mayer F.J. Future trends in incidence and management of prostate cancer. West J Med. 160:1994;380-381.
9. Haas G.P. Epidemiology of early prostate cancer. In Vivo. 8:1994;403-406.
10. Woolf H.S. Public health perspective the health policy implications of screening for prostate cancer . J Urol. 152:1994;1685-1688.
11. Dearnaley D.P. Cancer of the prostate. Br Med J. 308:1994;780-784.
12. Hall R.R. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer the argument against . Eur Urol. 29:(suppl 2):1996;24-26.
13. Labrie F., Cusan L., Gomez J.-L., et al. Combination of screening and pre-operative endocrine therapy the potential for an important decrease in prostate cancer mortality . J Clin Endocrinol Metab. 80:1995;2002-2013.
14. Mandelson M.T., Wagner E.H., Thompson R.S. PSA screening a public health dilemma . Annu Rev Public Health. 16:1995;283-306.
15. Iversen P., Adolfsson J., Johansson J.-E., et al. Localised prostate cancer - a Scandinavian view. Monogr Urol. 15:1994;93-112.
16. Blute M.L., Zincke H., Farrow G.M. Long-term follow up of young patients with stage A adenocarcinoma of the prostate. J Urol. 136:1986;840-843.
17. Epstein J.I., Paull G., Eggleston J.C., et al. Prognosis of untreated stage A1 prostatic carcinoma a study of 94 cases with extended follow up . J Urol. 136:1986;837-839.
18. Newling D.W., Hall R.R., Richards B. The natural history of prostatic cancer, the argument for a no treatment policy. Pavone-Macaluso M. Testicular Cancer and Other Tumours of the Genito-urinary Tract. 1985;443-449 Plenum, New York.
19. Moskovitz B., Nitecki A., Richter Levin D. Cancer of the prostate is there a need for aggressive treatment? Urol Int. 42:1987;49-52.
20. George N.J.R. Natural history of localized prostatic cancer managed by conservative therapy alone. Lancet. 1:1988;494-497.
21. Goodman C.M., Busuttil, Chisholm G.D. Age, and stage and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol. 62:1988;576-580.
22. Handley R., Carr T.W., Travis D., et al. Deferred treatment for prostate cancer. Br J Urol. 62:1988;249-253.
23. Orestano F. Problems of the wait-and-see policy in incidental carcinoma of the prostate. Altwein J.E., Faul P., Schneider W. Incidental Carcinoma of the Prostate. 1991;163-166 Springer, Berlin.
24. Whitmore W.F. Jr, Warner J.A., Thompson I.M. Expectant management of localized prostatic cancer. Cancer. 67:1991;1091-1096.
25. Adolfsson J., Carstensen J., Lowhagen T. Deferred treatment in clinically localized prostatic carcinoma. Br J Urol. 69:1992;183-187.
26. Jones G.W. Prospective, conservative management of localized prostate cancer. Cancer. 70:(suppl):1992;307-310.
27. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
28. Aus G., Hugosson J., Norlen L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol. 154:1995;460-465.
29. Johansson J.-E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer a prospective, population-based study in Sweden . N Engl J Med. 277:1997;467-471.
30. Brausi M., Palladini P.D., Latini A. "Watchful waiting" for clinically localized prostate cancer long term results . Eur Urol. 30:(suppl 2):1996;225. (abstract).
31. Iversen P., Adolfsson J., Johansson J.-E., et al. Localized prostate cancer a Scandinavian view . Monogr Urol. 15:1994;93-112.
32. Lu-Yao G.L., Yao S.-L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 349:1997;906-910.
33. Wilt T.J., Brawer M.K. The Prostate Cancer Intervention versus Observation Trial (PIVOT). Oncology. 11:1997;1133-1139.
34. Pezzinio G., Remington P.L., Anderson H.A., et al. Trends in the surgical treatment of prostate cancer in Wisconsin 1989-1991. J Natl Cancer Inst. 86:1994;1083-1086.
35. Gee W.F., Holtgrewe H.L., Albertsen P.C., et al. Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol. 154:1995;207-208.
36. Savage P., Bates C., Abel P., et al. British urological surgery practice. 1. Prostate cancer. Br J Urol. 79:1997;749-755.
37. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
38. Huland H. The risks outweigh the benefits of radical prostatectomy in localised prostate cancer the argument against . Eur Urol. 29:(suppl 2):1996;31-33.
39. Resnick M.I. Radical prostatectomy the perineal approach . Urology. 47:1996;457-459.
40. Oesterling J.E. Radical prostatectomy the retropubic approach . Urology. 47:1996;460-462.
41. Frazier H.A., Rovertson J.E., Paulson D.F. Radical prostatectomy the pros and cons of the perineal versus retropubic approach . J Urol. 147:1992;888-890.
42. Weldon V.E., Tavel F.R., Neuwirth H., et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol. 153:1995;1565-1569.
43. Walther P.J. Radical perineal vs. retropubic prostatectomy a review of optimal application and technical considerations in the utilization of these exposures . Eur Urol. 24:(suppl 2):1993;34-38.
44. Walsh P.C. Radical retropubic prostatectomy indication, technique, and long-term results . Oesterling J.E., Richie J.P. Urologic Oncology. 1997;147-161 WB Saunders, Philadelphia.
45. Reiner W.G., Walsh P.C. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol. 121:1979;198-200.
46. Pedersen K.V., Herder A. Radical retropubic prostatectomy for localized prostatic carcinoma a clinical and pathological study of 201 cases . Scand J Urol Nephrol. 26:1992;235-239.
47. Davidson P.J.T., van den Ouden D., Schröder F.H. Radical prostatectomy prospective assessment of mortality and morbidity . Eur Urol. 29:1996;168-173.
48. Lu-Yao G.L., McLerran D. An assessment of radical prostatectomy time trends, geographic variation, and outcomes . J Am Med Assoc. 269:1993;2633-2636.
49. Zincke H., Bergstralh E.J., Blute M.L., et al. Radical prostatectomy for clinically localized prostate cancer long-term results of 1,143 patients from a single institution . J Clin Oncol. 12:1994;2254-2263.
50. Dillioglugil O., Leibman B.D., Leibman N.S., et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 157:1997;1760-1767.
51. Gibbons R.P., Correa R.J., Brannen G.E., et al. Total prostatectomy for localized prostate cancer. J Urol. 131:1984;73-76.
52. Walsh P.C. Radical prostatectomy, preservation of sexual function, cancer control. Urol Clin North Am. 14:1987;663-673.
53. Lindner A., deKernion J.B., Smith R.B., et al. Risk of urinary incontinence following radical prostatectomy. J Urol. 129:1983;1007-1008.
54. Middleton R.G., Smith J.A., Melzer R.B., et al. Patients' survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol. 136:1986;422-424.
55. Igel T.C., Barrett D.M., Segyra J.W., et al. Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. J Urol. 137:1987;1189-1191.
56. Catalona W.J., Bigg S.W. Nerve-sparing radical prostatectomy evaluation of results after 250 patients . J Urol. 143:1990;538-544.
57. Fowler F.J., Roman A., Bary M.J., et al. Patient-reported complications and follow-up treatment after radical prostatectomy the National Medicare Experience, 1988-1990 (updated June 1993) . Urology. 42:1993;622-629.
58. Scardino PT: Surgical treatment of clinically localized prostate cancer: the role of combination therapy. 32nd Annual Meeting, May 18-21, 1996, Philadelphia, Educational Book, pp 230-236.
59. Bagshaw M.A., Cox R.S., Hancock S.L. Control of prostate cancer with radiotherapy long-term results . J Urol. 152:1994;1781-1785.
60. Hanks G.E., Hanlon A., Schultheiss T., et al. Early prostate cancer the national results of radiation treatment from the patterns of care and radiation therapy oncology group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation . J Urol. 152:1994;1775-1780.
61. Crook J.M., Bahadur Y.A., Bociek R.G., et al. Radiotherapy for localized prostate cancer. Cancer. 79:1997;328-336.
62. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.
63. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma? Cancer. 80:1997;442-453.
64. Schipper R.A., van Andel G., de Reijke T.M., et al. Prostate carcinoma treated by brachytherapy with I-125 is cure possible? Br J Urol. 80:(suppl 2):1997;239. (abstract).
65. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
66. Bostwick D.G., MacLennan G.T., Larson T.R. The American Cancer Society. Prostate Cancer What Every Man - and His Family - Needs to Know . 1996;Villard Books, New York.
67. Koutrouvelis P.G., Schwartz D.T., Mondalek P., et al. Stereotactic transgluteal CT-guided conformal brachytherapy of prostate cancer is not limited by prostate size, bone or urinary obstruction, or TURP defects. J Urol. 80:(suppl 2):1997;268. (abstract).
68. Koprowski C.D., Berkenstock K.G., Borofski A.M., et al. External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. Int J Radiat Oncol Biol Phys. 21:1991;955-960.
69. Brosman S.A., Tokita K. Transrectal ultrasound-guided interstitial radiation therapy for localized prostate cancer. Urology. 38:1991;372-376.
70. Marinelli D., Shanberg A.M., Tansey L.A., et al. Follow-up prostate biopsy in patients with carcinoma of the prostate treated by 192 iridium template irradiation plus supplemental external beam radiation. J Urol. 147:1992;922-925.
71. Bagshaw M.A., Cox R.S., Ray G.R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr. 7:1988;47-60.
72. Paulson D.F., Moul J.W., Robertson J.E., et al. Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J Urol. 143:1990;1178-1182.
73. Shipley W.U., Prout G.R. Jr, Coachman N.M., et al. Radiation therapy for localized prostate carcinoma experience at the Massachusetts General Hospital (1973-1981) . Wittes R.E. Consensus Development Conference on the Management of Clinically Localized Prostate Cancer, NCI Monographs. No. 7 (NIH publication no. 88-3005). 1988;67-73 Government Printing Office, Washington, DC.
74. Catalona W.J. Management of cancer of the prostate. N Engl J Med. 331:1994;996-1004.
75. Soffen E.M., Hanks G.E., Hunt M.A., et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques a reduction in acute morbidity . Int J Radiat Oncol Biol Phys. 24:1992;485-488.
76. Neal A.J., Oldham M., Dearnaley D.P. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol. 37:1995;29-34.
77. Kaplan I.D., Cox R.S., Bagshaw M.A. Radiotherapy for prostatic cancer patient selection and the impact of local control . Urology. 43:1994;634-639.
78. Bigg S.W., Kavoussi L.R., Catalona W.J. Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol. 144:1990;1420-1424.
79. Stamey T.A., Villers A.A., McNeal J.E., et al. Positive surgical margins at radical prostatectomy importance of the apical dissection . J Urol. 142:1990;1166-1173.
80. Stein A., deKernion J.B., Smith R.B., et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 147:1992;942-946.
81. Frazier H.A., Robertson J.E., Humphrey P.A., et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol. 149:1993;516-518.
82. McPhee M.S. Lasers in the treatment of cancer of the prostate an overview . Biomed Pharmacother. 40:1986;321-322.
83. Amin Z., Harries S.A., Lees W.R., et al. Interstitial tumour photocoagulation. Endosc Surg Allied Technol. 4:1993;224-229.
84. Chang S.-C., MacRobert A.J., Brown S.G. Transurethral and interstitial photodynamic therapy of canine prostate with meso-tetra-(M-hydroxyphenyl)chlorin applicability and future prospect . J Urol. 155:1996;354. (abstract).
85. Pisters L.L., Shellie M.S., Swanson D.A., et al. Which patients with locally recurrent prostate cancer can be cured by salvage cryotherapy? J Urol. 155:(suppl):1996;647. (abstract).
86. Onik G.M., Cohen J.K., Reyes G.D., et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 72:1993;1291-1299.
87. Bonney W.W., Henstorf J.E., Emaus S.P., et al. Immunostimulation by cryosurgery an orthotopic model of prostate and bladder cancer in the rat . Natl Cancer Inst Monogr. 49:1978;375-381.
88. Cespedes R.D., Pisters L.L., von Eschenbach A.C., et al. Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate results in 143 patients . J Urol. 157:1997;237-240.
89. White M.D., Loughlin M.W., Fisher H.A.G., et al. Voiding function in patients undergoing prostatic cryoablation - a preoperative urodynamic analysis. Br J Urol. 80:(suppl 2):1997;274. (abstract).
90. Moul J.W. An important goal of prostatectomy minimizing incontinence . Contemp Urol. 6:1994;15.
91. Gould R.S. New approaches to cryosurgery - comparisons to radical surgery. Br J Urol. 80:(suppl 2):1997;269. (abstract).
92. Chin J.L., Downey D.B., Mulligan M., et al. A new cryosurgery system for prostate cancer preliminary experience in non-surgical candidates . Br J Urol. 80:(suppl 2):1997;262. (abstract).
93. Lee F., Bahn D.K., McHugh T.A., et al. Cryosurgery of prostate cancer use of adjuvant hormonal therapy and temperature monitoring - a one year follow-up . Anticancer Res. 17:1997;1511-1516.
94. Debruyne F.M.J., Dijkman G.A. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol. 28:1995;177-188.
95. Ellis W., Isaacs J.T. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinoma. Cancer. 145:1985;6041-6050.
96. Huggins C., Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
97. Huggins C., Stevens R.E., Hodges C.V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 43:1941;209-223.
98. Debruyne F.M., Denis L., Lunglmayer G., et al. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol. 140:1988;775-777.
99. Emtage L.A., Trethowan C., Hilton C., et al. Interim report of a randomized trial comparing Zoladex 3 6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer . Am J Clin Oncol. 11:(suppl 2):1988;173-175.
100. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
101. Denis L., Murphy G.P. Overview of phase II trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 72:(suppl 3):1993;54-61.
102. Maximal androgen blockade in advanced prostate cancer an overview of 22 randomised trials with 3283 deaths in 5710 patients . Lancet. 346:1995;265-269.
103. Debruyne F.M., De Gery A., Hucher M., et al. Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer an updated metaanalysis of 7 randomised, placebo-controlled trials (1191 patients) . Eur Urol. 30:(suppl 2):1996;264. (abstract).
104. Janknegt R.A., Maastricht N.L. Long-term efficacy and safety of maximal androgen blockade (MAB) with nilutamide (Anandron) and castration in stage D2 prostate cancer. Eur Urol. 30:(suppl 2):1996;264. (abstract).
105. Schellhammer P.F., Sharifi R. Maximal androgen blockade for patients with metastatic prostate cancer outcome of a controlled trial of bicalutamide (Casodex) versus flutamide, each in combination with luteinising hormone releasing hormone analogue therapy . Urology. 47:(suppl 1A):1996;54-60.
106. Kaisary A.V., Tyrrell C.J., Peeling W.B., et al. Comparison of LH-RH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma. Br J Urol. 67:1992;502-508.
107. Trachtenberg J. Progress in complete androgen blockade. Eur Urol. 31:(suppl 2):1997;8-10.
108. Griffiths K., Eaton C.L., Harper M.E., et al. Hormonal treatment of prostate cancer some new aspects . Semin Oncol. 21:1994;672-687.
109. Varenhorst E. Orchidectomy, GnRH-analogues and anti-androgens in advanced carcinoma of the prostate. Laekemedelsverket. 3:1993;89-102.
110. Cassileth B.R., Seidmon E.J., Soloway M.S., et al. Patient's choice of the treatment in stage D prostate cancer. Urology. 33:1989;57-62.
111. Fossa S.D., Aass N., Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol. 21:1994;657-661.
112. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 124:1967;1011-1017.
113. Robinson M.R.G. Carcinoma of the prostate hormonal therapy . Clin Oncol. 1:1982;233-244.
114. Robinson M.R.G. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805 orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol . Cancer. 72:1993;3855-3857.
115. Chang A., Yeap B., Davis T., et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma flutamide versus diethylstilbestrol . J Clin Oncol. 14:1996;2250-2257.
116. Lunglmayr G., Girsch E. Patient choice in the treatment of advanced prostate cancer. R Soc Med Int Congr Symp Ser. 125:1987;47-53.
117. Dijkman G.A., Debruyne F.M., Fernandez del Moral P., et al. A randomised trial comparing the safety and efficacy of the Zoladex 3 6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer . Eur Urol. 27:1995;43-46.
118. Denis L.J., Carnelro de Moura J.L., Bono A., et al. Goserelin acetate and flutamide versus bilateral orchidectomy a phase II EORTC trial (30853) . Urology. 42:1993;119-130.
119. Brewster S.F., Gillatt D.A. Advanced prostate cancer what's new in hormonal manipulation? Br J Hosp Med. 49:1993;710-715.
120. Boccon-Gibod L., Laudat M.H., Dugue M.A., et al. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol. 12:1986;400-402.
121. Labrie F., Dupont A., Belanger A. A complete androgen blockade for the treatment of prostate cancer. De Vita V.T., Hellman S., Rosenberg S.A. Important Advances in Oncology. 1985;193-200 JB Lippincott, Philadelphia.
122. Labrie F., Luthy I., Veilleux R. New concepts on the androgen sensitivity of prostate cancer. Murphy G.P., Kuss R., Khoury E. Prostate Cancer. Part A: Research, Endocrine Treatment, and Histopathology . 1987;145-172 Alan R. Liss, New York.
123. Labrie F. Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am. 20:1991;845-872.
124. Denis L.J. Commentary on maximal androgen blockade in prostate cancer a theory put into practice? Prostate. 27:1995;233-240.
125. Dijkman G.A., Janknegt R.A., de Reijke T.M., et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol. 158:1997;160-163.
126. Klotz L.H., Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Can J Urol. 3:1996;246-250.
127. Eisenberger M., Crawford E.D., McLeod D., et al. A comparison of bilateral orchidectomy with or without flutamide in stage D2 prostate cancer (NCI INT-0105 SWOG/ECOG). Proc Am Soc Clin Oncol. 16:1997;2a. (abstract).
128. Gleave M., Bruchovsky N., Goldenberg S.L., et al. Intermittent androgen suppression rationale and clinical experience . Schröder F.H. Recent Advances in Prostate Cancer and BPH Proceedings of the 4th Congress on Progress and Controversies in Oncological Urology (PACIOU IV) . 1996;109-120 Parthenon, New York.
129. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report . Urology. 45:1995;839-844.
130. Tunn U.W. Intermittent endocrine therapy of prostate cancer. Eur Urol. 30:(suppl 1):1996;22-25.
131. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al: Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostate cancer: final analysis of a randomized phase II trial of the EORTC urological group. J Urol 136: 634-631, 1986.
132. Boccon-Gibod L, Fournier G, Bottet P, et al: Flutamide versus orchidectomy in patients with metastatic prostate carcinoma. Presented at the European Association of Urology (XIth Congress, Berlin, 1994).
133. Boccardo F., Decensi A.U., Guarneri D., et al. Anandron (RU 23908) in metastatic prostate cancer preliminary results of a multicentric Italian study . Cancer Detect Prev. 15:1991;501-503.
134. Decensi A.U., Boccardo F., Guarneri D., et al. Italian Prostate Cancer Project monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate . J Urol. 146:1991;377-381.
135. Bales G.T., Chodak G.W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 47:(suppl 1A):1996;38-43.
136. Iversen P., Tyrrell C.J., Kaisary A.V., et al. "Casodex" (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer results from two multicentre randomised trials at median follow-up of 4 years . Urology. 51:1998;389-396.
137. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 33:1998;447-456.
138. Drakos P.E., Gez E., Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer. 28A:1992;1932-1933.
139. Barradell L.B., Faulds D. Cyproterone a review of its pharmacology and therapeutic efficacy in prostate cancer . Drugs Aging. 5:1994;59-80.
140. Rabe T., Feldmann K., Grunwald K., et al. Liver tumours in women on oral contraceptives. Lancet. 334:1994;1568-1569.
141. Watanabe S., Yamasaki S., Tanae A., et al. Three cases of hepatocellular carcinoma among cyproterone users. Lancet. 334:1994;1567-1569.
142. Kaisary A.V. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate. 5:1994;27-33.
143. Delaere K.P., Van Thillo E.L. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol. 18:1991;13-18.
144. Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol. 59:1987;156-158.
145. Wysowski D.K., Freiman J.P., Tourtelot J.B., et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 118:1993;860-864.
146. Kolvenbag G.J., Blackledge G.R. Worldwide activity and safety of bicalutamide a summary review . Urology. 47:1996;70-79.
147. Dawson L.A., Chow E., Morton G. Fulminant hepatic failure associated with bicalutamide. Urology. 49:1997;283-284.
148. Adolfsson J., Steineck G., Whitmore W.F. Recent results of management of palpable clinically localized prostate cancer. Cancer. 72:1993;310-322.
149. Johansson J.E. Watchful waiting for early stage prostate cancer. Urology. 43:1994;138-142.
150. Byar D.P. The Veterans Administration Cooperative Urological Research Groups studies of cancer of the prostate. Cancer. 32:1973;1126-1130.
151. Kozlowski J.M., Ellis W.J., Grayhack J.T. Advanced prostatic carcinoma early versus late endocrine therapy . Urol Clin North Am. 18:1991;15-24.
152. Boccon-Gibod L. The management of localized cancer of the prostate. Eur Urol. 29:(suppl 2):1996;62-68.
153. Byar DP, and Corle D: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Study, in Byar DP, and Corle D (Eds): Consensus Development Conference in the Management of Clinically Localized Prostate Cancer. Bethesda, NCI Monograph 7, 1988, p 165.
154. Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council Trial . Br J Urol. 79:1997;235-246.
155. Denis L. Current trends of treatment. Denis L. The Medical Management of Prostate Cancer. II. ESO Monograph Series. 1991;89-100 Springer-Verlag, Heidelberg.
156. Kirk D. Medical Research Council trial of immediate versus deferred hormone treatment for advanced prostatic cancer. Urol Int. 2:1995;13-14.
157. Paulson D.F., Moul J.W., Walther P.J. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma long-term results . J Urol. 144:1990;1180-1184.
158. Stein A., deKernion J.B., Smith R.B., et al. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 147:1992;942-946.
159. Fair W.R., Cookson M.S., Stroumbakis N., et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer Memorial Sloan-Kettering Cancer Center results . Urology. 49:(suppl 3A):1997;46-55.
160. Cookson M.S., Sogani P.C., Russo P., et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer results of a phase II study . Br J Urol. 79:1997;432-438.
161. Schulman C.C., Debruyne F.M.J., Forster G., et al. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma three years of follow up of a European multicentric randomised study . Br J Urol. 80:(suppl 2):1997;259. (abstract).
162. Soloway M.S., Shairifi R., Wajsman Z., et al. Radical prostectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 month results. Br J Urol. 80:(suppl 2):1997;259. (abstract).
163. Klotz L.H., Goldenberg S.L., Bullock M., et al. Neoadjuvant androgen ablation prior to radical prostectomy (CUOG P-92) 24 month post-treatment PSA results . Br J Urol. 80:(suppl 2):1997;266. (abstract).
164. Aus G., Hugosson J., Abrahamsson P.-A., et al. Pretreatment with triptorelin before radical prostatectomy - a 3 year follow-up. J Urol. 157:1997;393. (abstract).
165. Gleave M., Goldenberg S.L., Jones E., et al. Biochemical and pathological effects of 8 months of neoadjuvant hormonal therapy - an update on 125 consecutive patients. Br J Urol. 80:(suppl 2):1997;259. (abstract).
166. Aso Y., Homma Y., Sakamoto A., et al. A randomized prospective study on radical prostatectomy alone versus radical prostatectomy preceded by androgen deprivation. Eur Urol. 30:(suppl 2):1996;210. (abstract).
167. Soloway M.S., Shairifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 154:1995;424-428.
168. Klein E.A. Hormone therapy for prostate cancer a topical perspective . Urology. 47:(suppl 1A):1996;3-12.
169. Rabbani F., Sullivan L.D., Goldenberg S.L., et al. Neoadjuvant androgen deprivation therapy before radical prostatectomy who is unlikely to benefit? Br J Urol. 79:1997;221-225.
170. Zelefsky M.J., Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer reducing the potential morbidity of therapy . Urology. 49:(suppl 3A):1997;38-45.
171. Pilepich M.V., Krall J.M., Al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma a randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
172. Candas B., Gomes J.L., Cusan L., et al. Effects of neoadjuvant and adjuvant combined androgen blockade associated to radiation therapy on serum PSA. Br J Urol. 80:(suppl 2):1997;259. (abstract).
173. Zagars G.K., Pollack A., von Eschenbach A.C. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 80:1997;764-775.
174. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339:1992;1-15.
175. Zincke H., Utz D.C., Taylor W.F. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer role of adjuvant treatment for residual cancer and in disease progression . J Urol. 135:1986;1199-1205.
176. D'Amico A.V., Whittington R., Malkowicz B., et al. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer the basis for an adjuvant therapy trial . J Clin Oncol. 15:1997;1465-1469.
177. Andriole G., Lieber M., Smith J., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 45:1995;491-497.
178. Cheng W.S., Frydenberg M., Bergstralh E.J., et al. Radical prostatectomy for pathological stage C prostate cancer influence of pathological variables and adjuvant treatment on disease outcome . Urology. 42:1993;283-291.
179. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
180. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis of carcinoma of the prostate treated with definitive radiotherapy (report of RTOG Protocol 85-31). Proc Am Soc Clin Oncol. 14:1995;239.
181. Pollack A., Zagars G.K., Kopplin R.N. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;13-20.
182. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J Am Med Assoc. 270:1993;948-954.
183. Mandelson M.T., Wagner E.H., Thompson R.S. PSA screening a public health dilemma . Annu Rev Public Health. 16:1995;283-306.
184. von Eschenbach A., Ho R., Murphy G.P., et al. American Cancer Society guidelines for the early detection of prostate cancer update, June 10, 1997 . Cancer. 80:1997;1805-1807.
185. Stephenson R.A., Stanford J.L. Population-based prostate cancer trends in the United States patterns of change in the era of prostate-specific antigen . World J Urol. 15:1997;331-335.
186. Middleton R.G., Thompson I.M., Austenfeld I.M. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148.
187. Fleming C., Wasson J.H. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. J Am Med Assoc. 269:1993;2650-2658.
188. Beck J.R., Kattan M.W., Miles B.J. A critique of the decision analysis for clinically localized prostate cancer. J Urol. 152:1994;1894-1899.
189. Sperduto P., Rose M., Jolitz G., et al. The cost-effectiveness of alternative treatment in prostate cancer. J Radiat Oncol Biol Phys. 30:1994;220.
190. National Inpatient Profile, October 1992-September 1993, HCIA, Inc., 1994.
191. Gelet A., Chapelon J.Y., Bouvier R., et al. Treatment of prostate cancer with transrectal focused ultrasound first clinical experience . Br J Urol. 80:(suppl 2):1997;265. (abstract).
192. Schulman C.C., Zlotta A.R., Wildschutz T., et al. A new modality of treatment of localized prostate cancer initial experience with radiofrequency interstitial tumor ablation (RITA) through a transperineal ultrasound-guided approach . Br J Urol. 80:(suppl 2):1997;267. (abstract).